• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inhibition by N-(phosphonacetyl)-L-aspartate of aspartate transcarbamylase activity and drug-induced cell proliferation in mice.

作者信息

Yoshida T, Stark G R, Hoogenraad J

出版信息

J Biol Chem. 1974 Nov 10;249(21):6951-5.

PMID:4418148
Abstract
摘要

相似文献

1
Inhibition by N-(phosphonacetyl)-L-aspartate of aspartate transcarbamylase activity and drug-induced cell proliferation in mice.
J Biol Chem. 1974 Nov 10;249(21):6951-5.
2
N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture.N-（膦酰基乙酰基）-L-天冬氨酸，一种天冬氨酸转氨甲酰酶的有效过渡态类似物抑制剂，可阻断培养的哺乳动物细胞的增殖。
J Biol Chem. 1974 Nov 10;249(21):6945-50.
3
Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).抗肿瘤药物N-（膦酰乙酰基）-L-天冬氨酸（PALA）的酶活性测定
Cancer Treat Rep. 1979 Jan;63(1):85-8.
4
A facile enzymatic technique for the estimation of nanomolar concentrations of N-phosphonacetyl-L-aspartic acid in plasma.
J Biochem Biophys Methods. 1980 Jan-Feb;2(1):29-35. doi: 10.1016/0165-022x(80)90071-8.
5
Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.N-（膦酰基乙酰基）-L-天冬氨酸在体外对人源和鼠源细胞生长的抑制作用
Cancer Lett. 1981 Mar;12(1-2):169-73. doi: 10.1016/0304-3835(81)90053-7.
6
Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.人正常及肿瘤细胞系中天冬氨酸转氨甲酰酶的动力学参数
Cancer Res. 1983 May;43(5):2277-82.
7
Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.N-（膦酰基乙酰基）-L-天冬氨酸对小鼠肿瘤及正常组织的体内外作用以及敏感性与增殖速率和天冬氨酸转氨甲酰酶水平的关系
Cancer Res. 1978 Feb;38(2):371-8.
8
An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.一种用于测量组织中N-膦酰基乙酰-L-天冬氨酸的酶促技术。
Cancer Treat Rep. 1978 Oct;62(10):1503-7.
9
N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.N-（膦酰乙酰基）-L-天冬氨酸协同增强5-氟尿嘧啶/α-2a干扰素对人结肠癌细胞系的细胞毒性。
Mol Pharmacol. 1993 Nov;44(5):1070-6.
10
Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.在一项针对Lewis肺癌的N-（膦酰乙酰基）-L-天冬氨酸耐药变体的生化设计试验中阿西维辛和N-（膦酰乙酰基）-L-天冬氨酸的治疗效果
Cancer Res. 1981 Mar;41(3):905-9.

引用本文的文献

1
Prognostic and Immunotherapeutic Predictive Value of CAD Gene in Hepatocellular Carcinoma: Integrated Bioinformatics and Experimental Analysis.CAD基因在肝细胞癌中的预后及免疫治疗预测价值：综合生物信息学与实验分析
Mol Biotechnol. 2025 Mar;67(3):1240-1255. doi: 10.1007/s12033-024-01125-6. Epub 2024 Apr 29.
2
Pyrimidine Biosynthetic Enzyme CAD: Its Function, Regulation, and Diagnostic Potential.嘧啶生物合成酶 CAD：功能、调控及其诊断潜力。
Int J Mol Sci. 2021 Sep 23;22(19):10253. doi: 10.3390/ijms221910253.
3
Deciphering CAD: Structure and function of a mega-enzymatic pyrimidine factory in health and disease.
解析 CAD：健康与疾病中巨型酶嘧啶工厂的结构与功能。
Protein Sci. 2021 Oct;30(10):1995-2008. doi: 10.1002/pro.4158. Epub 2021 Jul 22.
4
Design, synthesis, and bioactivity of novel inhibitors of E. coli aspartate transcarbamoylase.新型大肠杆菌天冬氨酸转氨甲酰酶抑制剂的设计、合成及生物活性
Bioorg Med Chem Lett. 2007 Apr 1;17(7):2086-90. doi: 10.1016/j.bmcl.2006.12.050. Epub 2006 Dec 21.
5
N-phosphonacetyl-L-isoasparagine a potent and specific inhibitor of Escherichia coli aspartate transcarbamoylase.N-膦酰乙酰-L-异天冬酰胺，一种对大肠杆菌天冬氨酸转氨甲酰酶有效的特异性抑制剂。
J Med Chem. 2006 Oct 5;49(20):5932-8. doi: 10.1021/jm0607294.
6
PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma.
Invest New Drugs. 1998;16(4):315-8. doi: 10.1023/a:1006292218890.
7
Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.对化疗抗代谢物的耐药性：补救途径参与和细胞对DNA损伤反应的一种功能。
Br J Cancer. 1997;75(7):935-45. doi: 10.1038/bjc.1997.164.
8
Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.N-膦酰乙酰-L-天冬氨酸与双嘧达莫联合治疗癌症的I期试验
Cancer Chemother Pharmacol. 1987;19(1):80-3. doi: 10.1007/BF00296262.
9
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.PALA联合5-氟尿嘧啶治疗晚期胰腺癌的II期试验。
Cancer Chemother Pharmacol. 1992;29(4):305-8. doi: 10.1007/BF00685949.
10
m-AMSA and PALA: two new agents in cancer chemotherapy.m-AMSA和PALA：癌症化疗中的两种新药物。
Cancer Chemother Pharmacol. 1979;3(3):135-41. doi: 10.1007/BF00262414.